184 related articles for article (PubMed ID: 7493344)
1. 67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma.
Becker WS; Behr TM; Cumme F; Rössler W; Wendler J; Kern PM; Gramatzki M; Kalden JR; Goldenberg DM; Wolf FG
Cancer Res; 1995 Dec; 55(23 Suppl):5771s-5773s. PubMed ID: 7493344
[TBL] [Abstract][Full Text] [Related]
2. Improved staging of B-cell non-Hodgkin's lymphoma patients with 99mTc-labeled LL2 monoclonal antibody fragment.
Blend MJ; Hyun H; Kozloff M; Levi H; Mills GQ; Gasparini M; Buraggi G; Hughes L; Pinsky CM; Goldenberg DM
Cancer Res; 1995 Dec; 55(23 Suppl):5764s-5770s. PubMed ID: 7493343
[TBL] [Abstract][Full Text] [Related]
3. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
Juweid M; Sharkey RM; Markowitz A; Behr T; Swayne LC; Dunn R; Hansen HJ; Shevitz J; Leung SO; Rubin AD
Cancer Res; 1995 Dec; 55(23 Suppl):5899s-5907s. PubMed ID: 7493367
[TBL] [Abstract][Full Text] [Related]
4. Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas.
Baum RP; Niesen A; Hertel A; Adams S; Kojouharoff G; Goldenberg DM; Hör G
Cancer; 1994 Feb; 73(3 Suppl):896-9. PubMed ID: 8306276
[TBL] [Abstract][Full Text] [Related]
5. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
[TBL] [Abstract][Full Text] [Related]
6. Single tumor cell uptake and dosimetry of technetium-99m Fab' or minute anti-CD22 in low-grade B-cell lymphoma.
Lindén O; Hindorf C; Tennvall J; Segrén S; Wingardh K; Strand SE
Cancer; 2002 Feb; 94(4 Suppl):1270-4. PubMed ID: 11877756
[TBL] [Abstract][Full Text] [Related]
7. 67Ga scintigraphy in B-cell non-Hodgkin's lymphoma: correlation of 67Ga uptake with histology and transferrin receptor expression.
Nejmeddine F; Raphael M; Martin A; Le Roux G; Moretti JL; Caillat-Vigneron N
J Nucl Med; 1999 Jan; 40(1):40-5. PubMed ID: 9935054
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma.
Vose JM; Colcher D; Gobar L; Bierman PJ; Augustine S; Tempero M; Leichner P; Lynch JC; Goldenberg D; Armitage JO
Leuk Lymphoma; 2000 Jun; 38(1-2):91-101. PubMed ID: 10811451
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.
Leung SO; Goldenberg DM; Dion AS; Pellegrini MC; Shevitz J; Shih LB; Hansen HJ
Mol Immunol; 1995 Dec; 32(17-18):1413-27. PubMed ID: 8643111
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunoscintigraphy (RIS) with bectumomab (Tc99m labeled IMMU-LL2, Lymphoscan) in the assessment of recurrent non-Hodgkin's lymphoma (NHL).
Lamonica D; Czuczman M; Nabi H; Klippenstein D; Grossman Z
Cancer Biother Radiopharm; 2002 Dec; 17(6):689-97. PubMed ID: 12537673
[TBL] [Abstract][Full Text] [Related]
11. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
Lindén O; Tennvall J; Cavallin-Ståhl E; Darte L; Garkavij M; Lindner KJ; Ljungberg M; Ohlsson T; Sjögreen K; Wingårdh K; Strand SE
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
[TBL] [Abstract][Full Text] [Related]
13. Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/non-tumor localization ratios.
Govindan SV; Griffiths GL; Michel RB; Andrews PM; Goldenberg DM; Mattes MJ
Cancer Biother Radiopharm; 2002 Jun; 17(3):307-16. PubMed ID: 12136523
[TBL] [Abstract][Full Text] [Related]
14. Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 citrate scanning in the assessment of lymphomas.
Ziegels P; Nocaudie M; Huglo D; Deveaux M; Detourmignies L; Wattel E; Marchandise X
Eur J Nucl Med; 1995 Feb; 22(2):126-31. PubMed ID: 7758499
[TBL] [Abstract][Full Text] [Related]
15. Comparison of gallium-67-citrate and thallium-201 scintigraphy in peripheral and intrathoracic lymphoma.
Waxman AD; Eller D; Ashook G; Ramanna L; Brachman M; Heifetz L; McAndrews P; Bierman H; Taub R; Avedo M; Wall F
J Nucl Med; 1996 Jan; 37(1):46-50. PubMed ID: 8544000
[TBL] [Abstract][Full Text] [Related]
16. Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma.
Arndt MA; Krauss J; Schwarzenbacher R; Vu BK; Greene S; Rybak SM
Int J Cancer; 2003 Dec; 107(5):822-9. PubMed ID: 14566834
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of radioimmunoscintigraphy of non-Hodgkin's lymphoma with radiolabelled LL2 monoclonal antibody, LymphoSCAN: preliminary results.
Gasparini M; Bombardieri E; Tondini C; Maffioli L; Hughes L; Burraggi GL; Goldenberg DM
Tumori; 1995; 81(3):173-8. PubMed ID: 7571023
[TBL] [Abstract][Full Text] [Related]
19. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.
Goldenberg DM; Horowitz JA; Sharkey RM; Hall TC; Murthy S; Goldenberg H; Lee RE; Stein R; Siegel JA; Izon DO
J Clin Oncol; 1991 Apr; 9(4):548-64. PubMed ID: 2066752
[TBL] [Abstract][Full Text] [Related]
20. Lymphoma imaging with a new technetium-99m labelled antibody, LL2.
Murthy S; Sharkey RM; Goldenberg DM; Lee RE; Pinsky CM; Hansen HJ; Burger K; Swayne LC
Eur J Nucl Med; 1992; 19(6):394-401. PubMed ID: 1618230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]